Business context and reporting period
This is CHF Solutions, Inc.’s Form 10-K for the fiscal year ended December 31, 2020, filed March 25, 2021. The filing identifies the company as CHF Solutions, Inc.; the supplied filing text does not identify it as Nuwellis. The business develops, manufactures, and commercializes the Aquadex ultrafiltration systems for patients with fluid overload. Its commercial focus includes critical care, heart failure, and, following 2020 FDA clearance, pediatric patients weighing at least 20 kg.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Net sales | $7.441 million | $5.511 million |
| Gross profit / gross margin | $4.057 million / 54.5% | $2.851 million / 51.7% |
| Operating loss | $17.028 million | $18.106 million |
| Net loss | $15.836 million | $18.114 million |
| Cash used in operating activities | $16.572 million | $16.367 million |
| Cash and cash equivalents at year-end | $14.437 million | $1.279 million |
- Revenue increased 35.0%, which management attributed to expansion of its sales, clinical education, and marketing footprint. Cost of goods sold rose 27.2%; selling, general and administrative expense increased 7.0%, while research and development expense declined 21.5%.
- Gross margin improved to approximately 54.5% from 51.7%. Management expects manufacturing scale efficiencies to support further margin improvement as volumes grow.
- Year-end current assets were $18.536 million and current liabilities $3.585 million, implying working capital of approximately $14.951 million. Total liabilities were $3.694 million; the filing reports no outstanding conventional borrowings at year-end. Finance-lease liabilities totaled $78,000, alongside operating-lease liabilities.
- Financing activities provided $30.016 million in 2020, principally from equity offerings and warrant exercises. The March 19, 2021 stock offering, after year-end, generated approximately $19.0 million net proceeds.
Material changes versus the prior period
- Sales rose $1.930 million year over year; operating loss narrowed by $1.078 million. Net loss included a $1.202 million foreign-currency translation gain from dissolving the Australian subsidiary; without that item, the improvement in reported net loss would be smaller.
- Cash increased by $13.158 million, mainly reflecting equity financing, while operating cash use remained elevated and broadly similar to 2019.
- The company completed a 1-for-30 reverse stock split in October 2020 and regained Nasdaq minimum-bid-price compliance. It raised capital through several 2020 offerings and warrant exercises, with further common-stock issuance in March 2021.
- FDA clearance to include pediatric patients weighing at least 20 kg was received in February 2020. The company launched the ULTRA pediatrics registry and anticipates enrollment of more than 500 patients.
Outlook, management commentary, risks, and unusual items
- Management provided no quantified revenue or earnings guidance. It expects modestly higher commercial investment in 2021, general and administrative costs broadly consistent with 2020, and modestly higher research and development spending for pediatric work.
- The company expects continuing losses and states that year-end 2020 capital resources were expected to support its operating plan through December 31, 2022. It also says further funding may be needed; there is no assurance that financing will be available on acceptable terms.
- COVID-19 had mixed effects: hospital access restrictions and changes to sales practices negatively affected activity in some areas, while the company estimates approximately 14% of 2020 U.S. revenue was driven by hospitals treating COVID-19 patients. Future effects were described as uncertain and potentially material.
- Revenue depends on a single commercial product and a concentrated customer base: the ten largest customers generated 47.5% of 2020 revenue, and the largest generated 10.5%. Medicare had not issued a favorable national coverage determination for Aquadex ultrafiltration; outpatient use was not reimbursed by Medicare and private payors as described in the filing.
- Clinical evidence is mixed: UNLOAD showed greater fluid and weight loss, while CARRESS found no difference in weight loss and an increase in creatinine versus diuretics. AVOID-HF was stopped early for business reasons and was underpowered.
- The 2020 net loss includes the $1.202 million subsidiary-dissolution gain. Loss per share is difficult to compare across years because of the reverse split, major changes in weighted-average shares, and preferred-stock deemed dividends.
- Independent auditors issued an unqualified opinion on the financial statements. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Confirm issuer identity and reporting period: this supplied 10-K is for CHF Solutions, Inc. and covers FY2020, not a standalone 2020 fourth quarter.
- Track revenue growth, gross-margin progression, customer concentration, and the sustainability of COVID-related demand.
- Assess cash burn against the stated runway, including the effect of the March 2021 offering and subsequent operating results.
- Review the full capital structure and potential dilution from warrants, preferred stock, equity awards, and later share issuances.
- Check progress and enrollment in the pediatric registry, reimbursement developments, and evidence supporting broader adoption of Aquadex.
- Monitor Nasdaq listing and stockholders’ equity requirements, as well as risks to financing availability and continued operations.